Plasma and lipoprotein a-tocopherol concentrations of four patients with familial isolated vitamin E deficiency and six control subjects were observed for 4 d after an oral dose (-15 mg) of RRR-a-tocopheryl acetate labeled with six deuterium atoms (d6-tocopherol). Chylomicron d6-tocopherol concentrations were similar in the two groups. d6-Tocopherol concentrations of plasma, very low (VLDL), low (LDL), and high (HDL) density lipoproteins were similar in the two groups only during the first 12 h; then these were significantly lower, and the rate of disappearance faster, in the patients. The times (t.u) of the maximum chylomicron d6-tocopherol concentrations were similar for the two groups, but t1.,,, values in the controls increased in the order: chylomicrons < VLDL . LDL -HDL, while the corresponding values in the patients were similar to the chylomicron t,. Thus, plasma d4-tocopherol in controls increased during chylomicron and VLDL catabolism, whereas in patients it increased only during chylomicron catabolism, thereby resulting in a premature and faster decline in the plasma tocopherol concentration due to a lack of d6-tocopherol secretion from the liver. We suggest that these patients are lacking or have a defective liver "tocopherol binding protein" that incorporates a-tocopherol into nascent VLDL. (J. Clin. Invest. 1990. 85:397-407.) deuterated a-tocopherol * tocopherol binding protein Introduction Humans do not readily become vitamin E deficient. It has been generally accepted that the quantities of vitamin E in the diet are adequate and that the vitamin E stores in the body are sufficient to prevent any symptoms of vitamin E deficiency from occurring even in the face of a prolonged absence of dietary vitamin E. However, vitamin E deficiency does occur in humans as a consequence ofa variety oflipid malabsorption syndromes, most notably as a result of cholestatic liver disease in children, and in the genetic disorders, abetalipoproteinemia and homozygous hypobetalipoproteinemia (as reviewed in 1).
Introduction
Humans do not readily become vitamin E deficient. It has been generally accepted that the quantities of vitamin E in the diet are adequate and that the vitamin E stores in the body are sufficient to prevent any symptoms of vitamin E deficiency from occurring even in the face of a prolonged absence of dietary vitamin E. However, vitamin E deficiency does occur in humans as a consequence ofa variety oflipid malabsorption syndromes, most notably as a result of cholestatic liver disease in children, and in the genetic disorders, abetalipoproteinemia and homozygous hypobetalipoproteinemia (as reviewed in 1).
From these studies it has been determined that vitamin E deficiency in humans causes a severe, debilitating spinocerebellar lesion. Specifically, the progressive development of ataxia and areflexia with a "dying back" of the peripheral nerves, along with spinocerebellar degeneration, are characteristic of vitamin E deficiency.
Recently, nine patients worldwide have been described who exhibit similar neurologic abnormalities and vitamin E deficiency, but have no evidence of fat malabsorption (2) (3) (4) (5) (6) (7) (8) . These patients all have normal lipid absorption, gastrointestinal, pancreatic, and intestinal function, and lipoproteins, but when consuming a normal diet, they have exquisitely low plasma vitamin E levels and develop neurologic abnormalities characteristic of vitamin E deficiency. With the addition of daily vitamin E supplements (400-1,200 IU) to the diet, normal plasma vitamin E levels can be maintained and in several patients improvements in neurologic function have been reported. When vitamin E supplementation is interrupted, plasma tocopherol falls sharply to suboptimal levels.
The four patients described in this report have been extensively evaluated (8) . An impairment in vibratory sensation is present in all four. Nerve damage is more severe in two of the patients who experience both truncal and limb ataxia with head titubation. The tocopherol levels in peripheral nerves were also deficient (9) . Supplementation with vitamin E (800-900 IU/d of all-rac-a-tocopheryl acetate) raised the serum tocopherol levels from almost undetectable to normal, stabilized the neurologic function in two patients and improved it in the other two. The ability of these patients to absorb tocopherol was tested using an oral dose ofvitamin E of 100 1U/kg of body weight (8) . The increase in serum tocopherol levels in response to the test dose was not different from that of control subjects but its rate of decrease in the patients was faster than in the controls. These findings led us to conclude that there was no defect in the absorption of pharmacological doses of vitamin E. However, the absorption of dietary amounts of vitamin E was not measured, nor was the reason for the rapid decrease in the plasma levels of tocopherol defined.
We have recently demonstrated that the kinetics of absorption and transport of vitamin E in plasma lipoproteins in normal human subjects can be studied using the newly available deuterated a-tocopherols (10) . The purpose of the present work was to compare in patients and normal subjects the absorption of dietary amounts of vitamin E and to follow its incorporation into plasma lipoproteins using this technique.
We demonstrate that the absorption of dietary quantities of vitamin E by patients with "familial isolated vitamin E defi-ciency" is normal and propose a mechanism to explain its subsequent rapid decline in their plasma.
Methods
Subjects. This study was carried out with the approval of the Institutional Review Boards of New York University Medical Center and the University of Colorado School of Medicine. The ages of the subjects and the exact amount of deuterated RRR-a-tocopheryl acetate consumed are shown in Table I . The patients have been described in detail in a previous publication and the patient number in that publication and this one correspond to the same individual (8) . Patients 1-3 are siblings; patient 4 is unrelated to the other patients and has the most severe neurologic abnormalities (11) . All four patients have normal serum cholesterol, triglyceride, and apolipoprotein B levels (Table VI, [8] ). The control subjects also had normal lipid values and no abnormalities of lipoprotein metabolism.
Deuterated a-tocopherols. The syntheses and analysis ofdeuterated a-tocopherols have been described previously (12, 13). 2R,4'R,8'R-a-(5,7-(C2H3)2)tocopheryl acetate (d6-RRR-a-tocopheryl acetate) was provided to the subjects as a source of hexadeuterated a-tocopherol with natural stereochemistry. 2-ambo-a-(5,7,8-(C2H3)3tocopherol (dgtocopherol), used as an internal standard, was added to each sample immediately before lipid extraction (10, 14) . Because ofthe small doses of d6-RRR-a-tocopheryl acetate administered it was necessary to analyze each sample in its entirety. The 
where C is d6-tocopherol concentration at time t, A is estimate of the term FD/V where FD is the fraction of the dose absorbed and V is the apparent volume of distribution; ki is absorption rate constant; and kd is excretion rate constant. Estimates of kd were obtained by computing the slope from a logarithmic plot of the d6-tocopherol concentration versus time (36-72 h) for each individual subject. These estimates were used as starting values to compute the parameters of the model, A, ki, and kd, using the non-linear regression (NONLIN) procedure of SAS using the actual data. These parameters were then used to obtain the time at which the peak in the d6-tocopherol concentration occurred, tmam = In (ki/kd)I(ki -kd). Values of t,,,, were calculated for plasma and lipoprotein fractions from each individual.
Results
To determine whether the patients with familial isolated vitamin E deficiency could absorb dietary amounts of vitamin E, patients and control subjects consumed a single dose of d6-tocopherol with breakfast, then blood samples were drawn at the indicated intervals. The plasma and lipoprotein do-and d6-atocopherol concentrations at all time points for the individual subjects are presented in the Supplementary Table. The average plasma d6-tocopherol concentrations, shown in Fig. 1 , were found to change differently over time in patients and controls (P < 0.0001). To assess whether these differences were related to absorptive or to postabsorptive phenomena, the staAbbreviations used in this paper: AUC, area under the curve; GLM, general linear models. tistical significance of the differences between the two groups at each time point were determined (Table II) . Both patients and controls had similar increases in their plasma d6-tocopherol concentrations up to 12 h, which has been shown to be the time interval of maximum triglyceride-rich lipoprotein secretion after a fat-rich meal (21) . After the 12-h time point, the plasma d6-tocopherol concentration began to decrease in the patients, while it continued to increase in the controls. During the 36-96-h period, it decreased in both groups with the patients having significantly lower d6-tocopherol concentrations ( Fig. 1 , Table II ).
Plots of the average d6-tocopherol concentrations in the four lipoprotein fractions isolated from patients and control subjects are shown in Fig. 2 (Fig. 2, B-D sence of(unlabeled) vitamin E in the plasma has no observable effect on the absorption or transport of the new, labeled vitamin E.
The AUC obtained by plotting the d6-tocopherol concentration against time (0-96 h) was calculated for the plasma and lipoprotein fractions ofeach individual subject (Table IV) . The AUCs of the chylomicron d6-tocopherol were not different for the two groups, while the AUC of the plasma d6-tocopherol in the control subjects was nearly three times that of the patients and reflects differences in the AUCs obtained for d6-tocopherol in VLDL, LDL, and HDL. The VLDL d6-tocopherol AUC was not statistically different between patients and controls, possibly because of contamination of VLDL by chylomicron remnants at the early time points, which would lead to elevated d6-tocopherol concentrations in the VLDL fraction (see Discussion).
The tm. values, the time at which the peak in the d6-tocopherol concentration occurred, were estimated from the kinetic model. The plasma ti. in the patients occurred at a much earlier time than did that of the controls (12±5 h compared with 21±6) (Fig. 3) (Table II) . Defective incorporation of d6-tocopherol into VLDL was demonstrated by the differences in the times at which the d6-tocopherol reached a maximum value in the plasma and each lipoprotein fraction. In the patients the tea values were all similar and were similar to the chylomicron tmas, whereas in the controls the tm. values increased in the order: chylomicrons < VLDL < LDL -HDL (Fig. 3 ).
We have previously described a mechanism for the incorporation and transport of vitamin E in plasma lipoproteins in normal subjects (10) . Vitamin E is secreted by the intestine in chylomicrons (23, 24), which subsequently undergo lipolysis The tm. values of the lipoprotein d6-tocopherol concentrations in the control subjects supports the concept oftocopherol fthe AUC (nmol-h per ml) were calculated using transport from the intestine to the liver with the maximal -ule of the d6-tocopherol concentrations in the secretion of tocopherol into the plasma dependent upon secreprotein fractions for each individual subject. Also tion from the liver. There were no significant differences be- (17) . This would be a nonspecific mechanism for the transfer of tocopherol to the VLDL, dependent on a high rate of transfer from chylomicrons to HDL during chylomicron catabolism. Since the peak in the d6-tocopherol concentrations occurred simultaneously in all of the lipoprotein fractions of the patients, the precise mechanism for the increase in the d6-tocopherol content ofthe VLDL cannot be determined with certainty.
Previously, this disorder has been suggested to result from a selective defect in vitamin E absorption (5). However, in that study the only test of absorption was the measurement of plasma levels of tocopherol after a 2-g dose of a-tocopheryl acetate. Similar to the results of the oral vitamin E tolerance test carried out in the four patients studied here (8), the plasma tocopherol levels in the patient described by Harding et al. (5) were found to increase to normal levels after 4 hours and remained elevated for 24 h. It is our contention that the absorption and secretion of tocopherol in chylomicrons is not impaired in these patients and that the catabolism ofchylomicrons following a large oral dose of vitamin E will provide the other plasma lipoproteins with tocopherol. However, if the dose of vitamin E is small, similar to dietary levels or the amounts fed in the present study, the amounts of tocopherol distributed to the lipoproteins during chylomicron catabolism is insufficient to maintain the plasma tocopherol at normal levels. Although the patients absorb tocopherol when they consume a diet containing vitamin E, and no vitamin E supplements, we suggest that the amounts that remain in the plasma are minuscule because the major route for tocopherol export from the liver into the plasma via VLDL is impaired. The kd rates shown in Table III also lend further support for this hypothesis. The patients, who do not have the capability to maintain plasma tocopherol levels via the proposed VLDL mechanism, have a faster rate of disappearance than do the control subjects.
This faster rate of disappearance from the plasma also results from the inability of the patients to incorporate tocopherol into VLDL. As discussed above HDL could exchange with triglyceride-rich lipoproteins transferring tocopherols to these lipoproteins, which are then taken up by the liver via the apo E receptor. Thus, vitamin E from the peripheral tissues or from chylomicron catabolism, which is exchanged onto HDL, is then exchanged back onto triglyceride-rich lipoproteins. Since these lipoproteins have a relatively short half-life compared with LDL or HDL, and are taken up by the liver, this results in a net transfer of tocopherol from the periphery to the liver. If the mechanism for secretion of tocopherol from the liver is impaired in the patients, then tocopherol would move from the plasma to liver to be sequestered and/or excreted. The inability ofthe liver to secrete tocopherol in VLDL would lead not only to a lower initial plasma tocopherol level, but also to a faster disappearance of vitamin E from the plasma. Plasma levels of vitamin E are also dependent upon slowly turning over pools (Burton, G. W., and K. U. Ingold, unpublished observations), but in the short time interval ofthis experiment these play a relatively unimportant role for the comparison between patients and controls.
To evaluate these data with respect to relevant information concerning catabolism of tocopherol we have surveyed the literature. Unfortunately, the nature of the major catabolic products of tocopherol are not known, nor is there much information on the measurement of the rates of disappearance or decay. In a very early study on the role of vitamin E in humans Horwitt et al. (29) placed males on a sharply reduced intake of vitamin E in a controlled diet. Plasma levels measured at monthly intervals fell very slowly, perhaps by 15% at the end ofthe second month and by 40% by the end ofthe first year. These findings suggest conservation ofplasma vitamin E, or maintenance of the level by release of tissue stores of tocopherol. The only tissue measured was red blood cells, and presumably the tocopherol levels in these cells is in equilibrium with plasma levels.
Patients with familial isolated vitamin E deficiency require 800 mg of supplemental vitamin E per day to achieve maintenance plasma levels that are not strikingly different from those in normal subjects taking an equivalent supplement. However, it has been observed that even after prolonged periods of vitamin E supplementation with maintenance of normal plasma levels of tocopherol (and presumably adequate tissue levels), interruption of vitamin E supplementation results in a plummeting of the plasma tocopherol levels in less than 72 h to values < 80% of maintenance levels. Our interpretation of these data is that there is no husbanding of tocopherol during passage through the liver and that since the mechanism for incorporation of tocopherol into VLDL is impaired the excretion into bile is complete and effective.
An alternative explanation for the observed altered clearance of plasma tocopherol in the patients might be a faster extrahepatic catabolism of vitamin E. There are several reasons why we do not believe that the patients have a faster catabolism of vitamin E. (a) The vitamin E molecule might be more rapidly catabolized if the molecule were "abnormal", but humans do not synthesize the vitamin; thus a defective product which would be rapidly catabolized and excreted is not likely. (b) If the abnormality was, for example, a defective enzyme involved in vitamin E catabolism, this would result more likely in an abnormal accumulation, not the disappearance, of vitamin E. (c) If the defect was a generalized more rapid oxidative process, one would expect to find other oxidized molecules accumulating in the plasma and tissues in addition to the rapid disappearance of vitamin E, but this has not been found (8) . (d) Finally, if a catabolic process were involved, one might expect that in the patient who had continued to take supplemental vitamin E, the d6-tocopherol might be spared by the excess unlabeled tocopherol present in the plasma. However, this was not observed. The unlabeled tocopherol in this patient decreased rapidly, as did the d6-tocopherol, which decreased at a rate similar to that in the other patients. When defined catabolic products can be measured in normal subjects and in patients, the issue of catabolism of tocopherol can be more clearly addressed. Taken together the available evidence suggests that the patients with familial isolated vitamin E deficiency are able to absorb vitamin E, this is transported normally to the liver, but the tocopherol then may be sequestered, or excreted, and the normal incorporation of tocopherol in VLDL is defective.
We propose that the incorporation of tocopherol into VLDL by the liver requires a specific "tocopherol binding Impaired Transport ofa-Tocopherol 403
protein." This function fits with the known properties of the tocopherol binding protein isolated from rat liver cytosol (30) (31) (32) . Further evidence for this mechanism in humans was demonstrated in our recent studies on the transport of a-and 'y-tocopherols (33) . Up to 12 h after oral administration of 1 g of each tocopherol, both tocopherols increased in the plasma of normal subjects, but by 24 h although the a-tocopherol remained elevated, the y-tocopherol concentration decreased.
By contrast, lipoprotein lipase deficient subjects, who have a defective chylomicron clearance, had elevated levels of both tocopherols at 24 h, while a subject with dysbetalipoproteinemia, who has a defective VLDL clearance, displayed the pattern of increased a-tocopherol and decreased y-tocopherol at 24 h. These data suggest that all forms of tocopherol are transported in chylomicrons, but the subsequent secretion in VLDL is fairly specific for a-tocopherol. The specificity of the incorporation of a-tocopherol into VLDL suggests that a protein is involved. In the absence of such a protein or if the function of this protein were impaired, tocopherol might be more readily metabolized and/or excreted in bile instead of being secreted into the plasma in VLDL. We hypothesize that this purported liver protein is either absent or defective in the patients with familial isolated vitamin E deficiency resulting in impaired transport of vitamin E to tissues other than the liver.
In conclusion, our data demonstrate that patients with familial isolated vitamin E deficiency absorb dietary amounts of a-tocopherol. However, less ofthe absorbed vitamin E in these patients is incorporated into VLDL, LDL, and HDL than in the controls. The mechanism by which control subjects secrete a-tocopherol from the liver appears defective in patients, and it is this inability to incorporate a-tocopherol into VLDL that results in a faster rate of disappearance of tocopherol from the plasma. We hypothesize that a tocopherol binding protein, which has been described in rat liver, may play an important role in incorporating a-tocopherol into VLDL, and may be absent or defective in these patients. 
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